Safety & Side Effects

Are Weight Loss Injections Safe?

Learn whether weight loss injections like Mounjaro and Wegovy are safe, including how they are regulated, common risks, and what to consider before starting.

Whether you are weighing up weight-loss injections for the first time or trying to make sense of conflicting media coverage, this guide is an honest answer to the question: are weight-loss injections safe? The short answer is "yes, for the right people, used through regulated UK channels, with awareness of the side effects" — but the longer answer is worth reading because the picture is genuinely more nuanced. LetsLoseWeight is an independent comparison site; we do not prescribe medication. The information below is for context, not personal medical advice.

What "safe" actually means in medicine

In medicine, no treatment is risk-free. "Safe" is shorthand for "the expected benefits outweigh the expected risks for the person taking it." That balance depends on who is taking it, why, in what dose, with what supervision, and from what supply chain.

For Mounjaro and Wegovy in the UK, the relevant pieces of evidence are:

  • The original clinical trials (the SURMOUNT and STEP programmes) which formed the basis of MHRA licensing
  • Post-marketing surveillance — including the MHRA Yellow Card scheme — which tracks side effects in real-world use
  • NICE technology appraisals (TA875 for Wegovy and TA1026 for Mounjaro) which explicitly weigh benefits, risks and cost-effectiveness for NHS use
  • A growing body of independent research and reviews

When asked "are they safe?", the regulators have answered yes — for the licensed indication, in the right population — by approving them. But there are caveats worth understanding.

What the trials show

The SURMOUNT-1 trial (tirzepatide) and STEP 1 trial (semaglutide) were both large, double-blind, placebo-controlled trials in adults with overweight or obesity. They found:

  • Average weight loss of around 15–21% over 72 weeks (tirzepatide, dose-dependent) and around 14.9% over 68 weeks (semaglutide 2.4mg)
  • Most side effects were gastrointestinal and most settled within weeks
  • Serious side effects were uncommon
  • Trial discontinuation due to side effects was around 4–7% — meaning over 90% of trial participants stayed on the medicine despite side effects

These are randomised clinical trial conditions. Real-world use is a bit different — patients are more diverse, less closely monitored, and may take other medicines that interact. But the overall picture is consistent with the trial data.

What's "uncommon" but real

Some side effects are rare but worth knowing about:

  • Acute pancreatitis — uncommon (up to 1 in 100). Severe upper-abdominal pain radiating to the back, with vomiting. Stop the medicine and seek urgent care.
  • Gallbladder problems — gallstones are common with Wegovy, uncommon with Mounjaro. Right-upper-abdominal pain, especially after fatty meals.
  • Severe allergic reactions — rare (up to 1 in 10,000). Face/throat swelling, breathing difficulty. A 999 emergency.
  • Acute kidney injury — uncommon, almost always in the context of severe vomiting or diarrhoea.
  • Diabetic retinopathy worsening — in people with type 2 diabetes only.

These are real risks but they are uncommon, and most can be caught and managed if patients know what to look for. For full detail, see our serious side effects guide.

What about the boxed warning?

Both medicines carry a warning about thyroid C-cell tumours, including medullary thyroid carcinoma (MTC). In animal studies (rats, mice), tirzepatide and semaglutide both caused these tumours. It is not known whether they cause the same in humans — long-term data in humans does not so far show an increased rate, but the FDA, EMA and MHRA take a precautionary approach.

The practical implication: anyone with a personal or family history of MTC, or with multiple endocrine neoplasia syndrome type 2 (MEN 2), should not take these medicines. Anyone else should report new neck symptoms (lumps, hoarseness, trouble swallowing) promptly.

Mental health — what's known and unknown

Concerns were raised in 2023 about reports of suicidal thoughts and self-harm in people taking GLP-1 medicines. The MHRA, EMA and FDA have all reviewed these reports.

The most recent reviews — published 2024 — have not found a causal link between GLP-1 medicines and suicidal thoughts. Large observational studies have not shown an increased rate compared with people taking other obesity treatments. But because the question matters and because regulators are cautious, monitoring continues, and patients and clinicians are asked to report any mental health concerns through the Yellow Card scheme.

If you experience low mood, suicidal thoughts or self-harm urges while on these medicines: contact your GP, NHS 111 (option 2 for mental health), or the Samaritans on 116 123 (free, 24/7).

What about long-term safety?

The longest published trials run to a few years and have not surfaced unexpected long-term safety problems. The semaglutide molecule has been used for diabetes since 2017 (and a similar molecule, liraglutide, since 2009), so the GLP-1 class as a whole has more than a decade of human data behind it. Tirzepatide is newer, with regulatory approval in 2022.

What remains genuinely uncertain at the longer end of the time horizon: whether very long-term use changes any low-frequency risks, what happens to muscle and bone in people who lose substantial weight quickly, and whether stopping after several years has cardiovascular consequences. Studies are ongoing.

The bigger safety risk most people miss

The single biggest avoidable safety risk in this category, in the UK, is not the side-effect profile of the licensed medicines. It is the unregulated supply — buying weight-loss injections from social media sellers, "weight-loss clinics" outside the regulated supply chain, foreign websites, or beauty clinics not registered with the GPhC.

The MHRA has issued public warnings about this. The risks include:

  • Counterfeit product — the vials may not contain the medicine they claim to, or may be contaminated.
  • Wrong doses — pre-filled pens supplied outside the regulated chain may be unreliable.
  • No clinical assessment — the medicines have contraindications and the assessment process is there to catch them.
  • No safety net — if something goes wrong, there is nobody to call.

A regulated UK pharmacy is registered with the General Pharmaceutical Council (GPhC), uses a UK-registered prescriber, and supplies medicines through licensed wholesalers. These are the providers who will appear in our provider listings.

Who shouldn't take weight-loss injections

Even allowing for the safety profile, the medicines are not suitable for everyone. Contraindications include:

  • Personal or family history of medullary thyroid carcinoma or MEN 2
  • Hypersensitivity to the active ingredient
  • Pregnancy or breastfeeding

Cautions apply for type 1 diabetes, severe gastrointestinal disease, history of pancreatitis, diabetic retinopathy, eating disorders, and significant kidney or liver impairment.

For the full list, see our eligibility guide.

So — are they safe?

For someone meeting the licensed eligibility criteria, prescribed through a regulated UK pharmacy, with proper clinical assessment and follow-up, the trial evidence and regulatory reviews suggest the benefits typically outweigh the risks. That is what "safe" means in medicine.

That does not mean side-effect-free. Most patients experience some gastrointestinal upset. A small minority experience more serious side effects. Knowing what to watch for, and using a regulated provider, is the difference between a manageable risk profile and an avoidable one.

For a personal answer to whether the medicines are safe for you, that is a decision for a qualified prescriber based on your medical history, current medications, and goals.

Frequently asked questions

Are weight-loss injections safer than weight-loss surgery?
Short-term, yes — the surgical risks of bariatric surgery are higher than the risks of starting a weight-loss injection. Long-term, the comparison is more nuanced because surgery is permanent and the medicines are not. Each has different risk and benefit profiles and they are not direct substitutes; some patients move between them.

Are weight-loss injections safer than no treatment for obesity?
Untreated obesity carries its own substantial risks (cardiovascular disease, diabetes, certain cancers, joint disease). For someone meeting eligibility criteria, the trial evidence shows treatment benefits outweighing treatment risks. That is implicit in the NICE recommendations.

What about media reports of deaths linked to weight-loss injections?
Most UK media coverage of deaths has involved unregulated supply — counterfeit product or non-clinical settings. Reported deaths in regulated patients have generally not been clearly causally linked to the medicines themselves; the MHRA reviews each report through the Yellow Card scheme.

Will I have side effects forever?
Most common side effects settle within a few weeks of starting or stepping up. A small minority of patients have persistent symptoms severe enough that they stop the medicine.

Next steps

Sources

This guide is for general information only and is not a substitute for professional medical advice. Talk to a qualified prescriber about whether weight-loss injections are suitable for you.

Get weekly weight loss tips

Join our newsletter for provider updates, expert guidance, and exclusive offers — no spam.

Subscribe free
Back to Guides
Are Weight Loss Injections Safe? An Honest UK Guide | LetsLoseWeight